BioSpace News Archive

Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments

Deepening Usage of ANJESO Evidenced by a Reorder Rate of 60% by the End of 2020 and 58% Growth in Vials Sold from the Sequential Quarter

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that HOOKIPA’s management team will participate in the upcoming virtual SVB Leerink Global Healthcare Conference

Signature Biologics, LLC. announced that the U.S. Food and Drug Administration has approved an IND Application to proceed with the study of Signature Cord Prime™ in patients with symptomatic osteoarthritis of the knee with our Principal Investigator.

RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 years after RGX-314 administration Durable treatment effect observed with stable visual acuity,

-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced the first patient has been dosed in a Phase 2 study of NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), in combination with Bristol Myers Squibb’s Opdivo® (nivolumab), a PD-1 blocking antibody, versus nivolumab monotherapy.

Members include preeminent international scientific and clinical thought leaders in gene therapy, diseases of the central nervous system, and drug discovery and development

FDA stated it is not currently planning to hold an advisory committee meeting Potential for Vicineum to be a best-in-class treatment with projected peak revenue of $1B-$3B globally, $400M-$900M in the US Company to hold conference call at 8am ET

LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients.